Article Text

Download PDFPDF
Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum
  1. A Murashima1,2,
  2. N Watanabe1,2,
  3. N Ozawa1,
  4. H Saito1,
  5. K Yamaguchi1,2
  1. 1
    Department of Perinatology, National Center for Child Health and Development, Tokyo, Japan
  2. 2
    Japan Drug Information Institute in Pregnancy, Tokyo, Japan
  1. Correspondence to Dr A Murashima, Division of Maternal Medicine, Department of Perinatology, National Center for Child Health and Development, Okura 2-10-1, Setagaya-ku, Tokyo 157-8535, Japan; murasima-a{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Women with rheumatoid arthritis (RA) appear to be at a high risk of preterm delivery, preeclampsia and low birth weight infants.1 Reduction of inflammatory activity is of particular importance in those desirous of having children.2 3 The use of disease-modifying antirheumatic drugs, including biological preparations, has been shown to be essential for suppression of the activity of RA. Tumour necrosis factor inhibitors have been introduced for the treatment of RA, with the expectation of obtaining immediate and certain effect. Although no teratogenicity of these drugs has been recognised in animal experiments,4 5 the safety of their use in pregnancy has not yet been adequately established. In this …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.